Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?

Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$13.98 and traded as high as C$14.88. Fennec Pharmaceuticals shares last traded at C$14.88, with a volume of 101 shares trading hands.

Fennec Pharmaceuticals Price Performance

The stock has a market capitalization of C$516.89 million, a price-to-earnings ratio of -51.31 and a beta of 3.55. The firm has a 50 day simple moving average of C$13.98 and a 200-day simple moving average of C$11.65.

Insider Transactions at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov sold 9,747 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of C$13.23, for a total transaction of C$128,952.81. Following the sale, the director directly owned 2,746,104 shares of the company’s stock, valued at C$36,330,955.92. This represents a 0.35% decrease in their ownership of the stock. Also, Director Chris Anigeron Rallis sold 8,346 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of C$9.67, for a total value of C$80,705.82. Following the completion of the transaction, the director owned 61,314 shares in the company, valued at approximately C$592,906.38. This represents a 11.98% decrease in their position. 16.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A hedge fund recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned approximately 0.30% of Fennec Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 14.40% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.